TPA for stroke: Important progress in achieving faster treatment

JAMA

Volumn 311, Issue 16, 2014, Pages 1615-1617

  Grotta, James C ^a  

^a MEMORIAL HERMANN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EDITORIAL; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MEDICAL SERVICE; PATIENT CARE; PRIORITY JOURNAL; SYMPTOM; THERAPY DELAY; TIME TO TREATMENT; TOTAL QUALITY MANAGEMENT; TREATMENT INDICATION; TREATMENT OUTCOME;

BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; QUALITY IMPROVEMENT; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84898831063     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.3322     Document Type: Editorial

References (19)

1. Tissue plasminogen activator for acute ischemic stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587.
2. Hacke W, Donnan G, Fieschi C, et al ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-774.
3. Lees KR, Bluhmki E, von Kummer R, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695-1703.
4. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55(11):1649-1655.
5. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke. 2009;40(6):2079-2084.
6. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480-2488.
7. Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123(7):750-758.
8. Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA. doi:10.1001/jama.2014.3203.
9. Ebinger M, Winter B, Wendt M, et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA. doi:10.1001/jama.2014.2850.
10. Walter S, Kostopoulos P, Haass A, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol. 2012;11(5):397-404.
11. Broderick JP, Palesch YY, Demchuk AM, et al Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893-903.
12. Ciccone A, Valvassori L, Nichelatti M, et al SYNTHESIS Expansion Investigators. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368(10):904-913.
13. Kidwell CS, Jahan R, Gornbein J, et al;MR RESCUE Investigators. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368(10):914-923.
14. Wahlgren N, Ahmed N, Dávalos A, et al; SITS investigators. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372(9646):1303-1309.
15. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79(4):306-313.
16. Ebinger M, Wendt M, Rozanski M, et al. Golden hour-thrombolysis by starting treatment before hospital arrival: the Pre-Hospital Acute Neurological Treatment and Optimization of Medical care in Stroke study (PHANTOM-S). Stroke. 2014;45(suppl 1):A104.
17. Wu T, Nguyen C, Ankrom C, Yang J, Vahidy F, Grotta J, et al. Pre-Hospital Utility of Rapid Stroke evaluation Using In-ambulance Telemedicine (PURSUIT): a pilot feasibility study. Stroke. 2014;45(suppl 1):ATMP49.
18. Go AS, Mozaffarian D, Roger VL, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics: 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):399-410.
19. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996;27(9):1459-1466. (Pubitemid 26295889)